Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.

Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.

The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is one of several announced by high-ranking FDA leaders ahead of the coming ...

It will be co-led by Patrizia Cavazzoni, director of the FDA's Centre for Drugs Evaluation and Research (CDER), and Centre for Biologics Evaluation and Research (CBER) director Peter Marks.

With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...

Dr. Scott Manthei of the Nevada Ear and Sinus Institute has been advising patients against taking drugs like Sudafed for ...

Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a letter to the company. Enforcement discretion: The FDA order includes grace periods for different ...

None of that's going to change.” Yet the FDA will be without a number of veteran leaders, including Namandjé Bumpus and Patrizia Cavazzoni, who have stepped down or announced plans to depart ...